Genetic and Molecular Insights into Early Onset Coronary Heart Disease: A Survey

www.surveyx.cn

Abstract

Early onset coronary heart disease (CHD) represents a significant public health concern due to its contribution to premature morbidity and mortality globally. This survey paper explores the genetic and molecular factors influencing the development of CHD, emphasizing the role of high-throughput sequencing technologies in uncovering genetic variations and predispositions. The paper highlights the complex interplay of genetic polymorphisms, such as those in the CYP2C19 gene, and environmental factors in CHD risk, with a focus on inherited conditions like familial hypercholesterolemia. It discusses the integration of genomic, epigenomic, transcriptomic, and metabolomic data to elucidate CHD pathophysiology and the impact of single-nucleotide polymorphisms (SNPs) and gene-environment interactions. The survey outlines advancements in high-throughput sequencing, including single-cell RNA sequencing, and their applications in cardiovascular genomics, addressing computational challenges and proposing solutions. It also examines the genetic basis of familial hypercholesterolemia and its implications for CHD risk, advocating for improved diagnostic and management strategies. The paper underscores the importance of pharmacogenomics and personalized medicine in optimizing CHD treatments and highlights innovative therapeutic strategies targeting genetic pathways. Finally, it calls for future research to focus on multi-omics integration, personalized interventions, and overcoming computational barriers to advance the understanding and management of CHD.

1 Introduction

1.1 Significance of Early Onset Coronary Heart Disease

Early onset coronary heart disease (CHD) represents a significant public health concern due to its substantial contribution to premature morbidity and mortality worldwide. The prevalence of early onset CHD varies across populations, shaped by a complex interplay of genetic and environmental factors. For instance, genetic variations in the CYP2C19 gene, particularly within the Hakka population, highlight the necessity of understanding genetic diversity for effective pharmacotherapy and disease management [1]. Despite the wealth of genomic data, the genetic underpinnings of cardiovascular diseases remain inadequately understood, underscoring the clinical relevance of early onset CHD [2].

The genetic architecture of coronary artery disease (CAD) is intricate, involving multiple genetic variants that influence disease risk [3]. The clinical relevance of early onset conditions is further illustrated by research linking age at diagnosis with increased risks of excess mortality and cardiovascular disease, as seen in type 1 diabetes [4], emphasizing the need for early intervention strategies.

Additionally, the role of circulating lipoprotein lipids in the pathogenesis of CHD is well-established, necessitating a comprehensive understanding of the mechanisms involved to enhance predictive and preventive measures [5]. The integration of lipidomics into cardiovascular research is vital for



Figure 1: chapter structure

transcending traditional lipid measurements and addressing knowledge gaps regarding lipid roles in early onset CHD.

The multifactorial nature of early onset CHD, encompassing genetic, environmental, and molecular factors, requires a holistic approach to improve clinical outcomes and inform public health initiatives. The prevalence of dyslipidemia and its implications for cardiovascular risk in children accentuate the significance of early vascular aging as an indicator of cardiovascular risk [6]. Furthermore, the challenge of accurately predicting atherosclerosis risk factors, a chronic condition leading to severe cardiovascular events, further highlights its clinical importance [7].

Moreover, the integration of clinical and RNA-seq data through advanced predictive models has demonstrated improved survival predictions in high-dimensional contexts, offering insights into early onset CHD management [8]. Nutritional and genetic factors significantly influence cardiovascular disease development and progression, reinforcing the necessity for personalized dietary and genetic interventions [9].

1.2 Genetic and Molecular Factors in CHD Development

The development of coronary heart disease (CHD) is profoundly influenced by a complex interplay of genetic and molecular factors. The integration of genomic, epigenomic, transcriptomic, and metabolomic data has been pivotal in elucidating the pathophysiological mechanisms underlying CHD [2]. Genetic variations, particularly single-nucleotide polymorphisms (SNPs), are critical determinants of cardiovascular disease risk, warranting further exploration of their functional implications [10].

Recent advancements in single-cell genomics have unveiled insights into cellular heterogeneity and molecular mechanisms of cardiovascular diseases, presenting potential avenues for therapeutic interventions [11]. The genetic predisposition to CHD is further complicated by gene-environment interactions, as illustrated by the influence of genetic factors on diabetic nephropathy and cardiovascular disease risk in individuals with type 1 diabetes [12], necessitating a dual consideration of genetic and environmental determinants in CHD risk assessment [13].

MicroRNA gene polymorphisms have emerged as modulators of atherosclerotic cardiovascular disease, with specific SNPs associated with altered disease susceptibility [14]. Additionally, accurate assessment of copy number variations (CNVs), such as the KIV-2 repeat in the LPA gene, is essential for evaluating cardiovascular risk, underscoring the importance of precise genomic analyses [15].

The role of genetic predisposition in conditions like Antiphospholipid Syndrome (APS) highlights the involvement of major histocompatibility complex (MHC) genes in cardiovascular diseases, suggesting shared genetic pathways between CHD and autoimmune disorders [16]. Furthermore, the interaction between genetic variation and dietary factors significantly influences cardiovascular disease biomarkers and progression, emphasizing the importance of personalized interventions in managing CHD risk [9].

Advanced computational models that address gene-environment interactions in genome-wide association studies (GWAS) are crucial for unraveling the complexities of CHD [17]. These models facilitate the identification of key genetic contributors to CHD by integrating multiple genes and their interactions [18].

1.3 Structure of the Survey

This survey is meticulously structured to comprehensively explore the genetic and molecular insights into early onset coronary heart disease (CHD). The introductory section emphasizes the significance of early onset CHD alongside its genetic and molecular foundations, highlighting the role of high-throughput sequencing and cardiovascular genomics in advancing disease understanding. Following this, the prevalence and clinical implications of early onset CHD are examined, stressing the importance of genetic diversity in disease management.

The subsequent section, Background and Core Concepts, elucidates key concepts such as atherosclerosis, genetic polymorphism, genetic predisposition, and familial hypercholesterolemia, which are fundamental to understanding CHD pathogenesis and risk factors. In particular, the atherosclerosis section discusses its pathogenesis and implications, while the role of genetic polymorphisms is explored in the context of disease development.

Advancements in high-throughput sequencing technologies are addressed in the third section, focusing on their applications in cardiovascular genomics, particularly in identifying genetic variations related to CHD. This section also tackles the computational challenges of sequencing data analysis and proposes potential solutions.

The fourth section delves into specific genetic polymorphisms and predispositions associated with early onset CHD, exploring methods for identifying and analyzing genetic variants linked to increased CHD risk. Multi-omics approaches are also discussed for their contribution to enhancing our understanding of genetic predispositions.

The fifth section examines familial hypercholesterolemia and its genetic basis, discussing the genetic underpinnings and diagnostic challenges associated with this condition, alongside recent advances in familial hypercholesterolemia identification [16].

The penultimate section discusses the implications of genetic and molecular insights for interventions and treatments of early onset CHD. It outlines current management and treatment strategies, the role of pharmacogenomics in personalized medicine, and innovative therapeutic strategies targeting genetic pathways. The contribution of multi-omics approaches to precision health in CHD treatment is also examined [9].

Finally, the conclusion synthesizes key findings, emphasizing the importance of integrating genetic and molecular insights into clinical practice. The discussion encompasses future research directions and challenges in next-generation sequencing and multi-omics data integration, highlighting the need for innovative deep learning approaches to overcome existing bottlenecks and enhance understanding of complex biological systems, thereby paving the way for continued advancements in precision medicine and personalized healthcare [19, 20, 21, 22].The following sections are organized as shown in Figure 1.

AI-generated, for reference only.

2 Background and Core Concepts

2.1 Atherosclerosis: Pathogenesis and Implications

Atherosclerosis, a chronic inflammatory arterial disease, is a major contributor to global morbidity and mortality, particularly through coronary heart disease (CHD) [23]. It involves lipid and cholesterol accumulation in arterial walls, leading to plaque formation that narrows and hardens arteries [24]. Its pathogenesis is multifactorial, involving genetic, molecular, and environmental factors [25].

Immune responses are pivotal in atherosclerosis progression, with macrophages, T cells, and B cells influencing plaque stability [26]. Chronic inflammation, due to unresolved immune responses, exacerbates lesions [27]. Macrophages exhibit impaired anti-inflammatory behavior within plaques, enhancing inflammation and instability [24].

Endothelial dysfunction initiates atherosclerosis, followed by lipid accumulation and plaque formation [25]. Oxidized low-density lipoproteins (LDL) are crucial in atherogenesis, accumulating in the arterial intima. Media dysfunction from smooth muscle cell injury initiates atherosclerosis, altering vessel mechanics and promoting granulation tissue formation [23].

Targeting inflammatory pathways offers promising strategies for reducing atherosclerotic risk [28]. The complex interactions between immune cells and atherosclerosis enhance understanding of disease mechanisms and therapeutic targets [26]. However, the roles of specific immune cell subsets in atherosclerosis, especially between human and animal models, remain unclear [26].

Genetic factors significantly influence atherosclerosis, with numerous variants increasing coronary artery disease (CAD) susceptibility [3]. The interplay between genetic variations and diet affects cardiovascular biomarkers, highlighting personalized nutrition's role in managing CVD risk [9]. Advanced statistical models are employed to elucidate gene-environment interactions in cardiovascular genomics, particularly in atherosclerosis [29].

Atherosclerosis accelerates CAD development and complicates early onset CHD management due to its complex pathogenesis. Understanding its molecular and cellular mechanisms is vital for developing targeted interventions and improving clinical outcomes. Investigating cellular participants and inflammatory pathways offers therapeutic avenues to mitigate its impact [30].

2.2 Genetic Polymorphisms and Their Role in CHD

Genetic polymorphisms significantly influence the susceptibility and progression of early onset coronary heart disease (CHD) by affecting biological pathways crucial to cardiovascular health. Variations in genes like CYP2C19 impact drug metabolism, emphasizing the importance of genetic testing in optimizing cardiovascular therapies [1]. These variations can alter treatment efficacy and safety, underscoring personalized medicine's role in cardiovascular care.

Polymorphisms in lipid metabolism genes are critical in atherosclerosis and CHD pathogenesis, affecting LDL cholesterol, triglycerides, and apolipoprotein B, and thus influencing CHD risk [5]. Assessing lipid-related genetic traits is essential for comprehensive cardiovascular risk evaluation.

The interplay between genetic polymorphisms and immune function is also crucial. Variations in genes regulating immune responses, such as those involving the NLRP3 inflammasome and toll-like receptors, are implicated in inflammatory pathways driving atherosclerosis and early onset CHD [30]. Understanding these pathways is vital for identifying therapeutic targets to modulate immune responses and mitigate CHD.

Genetic polymorphisms also interact with environmental factors, influencing atherosclerosis development. Identifying genes involved in atherosclerosis and their environmental interactions remains complex, as traditional statistical methods in high-throughput genomics have not fully addressed these interactions [29]. Advanced analytical approaches are required to unravel these intricate gene-environment interactions, essential for understanding the multifactorial nature of CHD.

2.3 Genetic Predisposition: Interplay with Environmental Factors

The interplay between genetic predisposition and environmental factors is critical in determining early onset coronary heart disease (CHD) risk. Genetic predispositions, such as variations in genes like ACE2, significantly influence cardiovascular disease susceptibility, modulated by environmental factors [16]. This necessitates a comprehensive risk assessment approach integrating both genetic and environmental determinants [4].

A significant challenge is the computational intensity required to accurately identify single nucleotide polymorphisms (SNPs) within extensive datasets, particularly when using nonlinear mixed-effect models (NLMM), which demand substantial computational resources and may face convergence issues [31]. Integrating multi-omics data, including genomics, proteomics, and epigenomics, is crucial for elucidating complex interactions between genes, proteins, and environmental factors in CHD [16]. This multidimensional approach provides a nuanced understanding of genetic predispositions' manifestation in environmental contexts.

The complexity of cardiovascular diseases poses challenges in understanding their molecular mechanisms through traditional genetic studies. This complexity is compounded by variability in drug metabolism due to genetic polymorphisms, such as those in the CYP2C19 gene, affecting pharmacotherapy outcomes and highlighting the need for personalized treatment strategies. Additionally, the interaction between genetic factors and lipid metabolism is vital in CHD risk, with unresolved questions about the full spectrum of lipid species and their interactions with genetic factors [6].

Environmental factors, particularly early life conditions, significantly interact with genetic predispositions to influence heart disease risk [4]. These interactions emphasize the importance of considering both genetic and environmental determinants in CHD risk assessment, as they collectively shape the disease's trajectory. Advanced computational approaches, such as integrating diverse omics modalities and environmental factors, are essential for addressing high-dimensional data challenges and capturing nonlinear interactions among various data types.

In recent years, high-throughput sequencing has revolutionized the field of cardiovascular genomics, enabling unprecedented insights into genetic variations and their implications for personalized medicine. As illustrated in Figure 2, the hierarchical structure of high-throughput sequencing encompasses various advancements in sequencing technologies. This figure not only highlights the applications of these technologies in identifying genetic variations but also addresses the computational challenges that arise in this rapidly evolving field, along with potential solutions. Such a comprehensive overview underscores the importance of integrating technological advancements with clinical applications to enhance our understanding of cardiovascular diseases.



Figure 2: This figure illustrates the hierarchical structure of high-throughput sequencing in cardiovascular genomics, detailing advancements in sequencing technologies, applications in genetic variation identification and personalized medicine, and computational challenges and solutions.

3 High-Throughput Sequencing in Cardiovascular Genomics

3.1 Advancements in High-Throughput Sequencing Technologies

High-throughput sequencing (HTS) technologies have revolutionized cardiovascular genomics, offering profound insights into the genetic and molecular bases of coronary heart disease (CHD). The transition from first-generation to next-generation sequencing (NGS) and single-molecule sequencing (SMS) has been instrumental in deciphering CHD's intricate genetic framework [21]. These technologies have facilitated extensive genetic variation analyses, leading to the discovery of novel biomarkers and therapeutic targets.

As depicted in Figure 3, this figure illustrates the key advancements in high-throughput sequencing technologies for cardiovascular research, focusing on sequencing innovations, data integration methodologies, and lipid metabolism pathways in coronary heart disease. Single-cell RNA sequencing (scRNA-seq) stands out by revealing cellular diversity within cardiovascular tissues, aiding in identifying cell-type-specific gene expression patterns and enhancing our understanding of CHD pathogenesis [32]. Tools like Demuxlet refine scRNA-seq analyses by accurately assigning cell identities in droplet-based experiments [33].

The integration of high-dimensional genomic data into cardiovascular research is driven by novel computational methodologies. Wavelet-based genetic association analysis (WGA) employs wavelet transforms on high-resolution sequencing data to identify genetic variants linked to chromatin accessibility [34]. Percolation theory from statistical physics provides a framework for understanding signal propagation in complex genetic networks [35].

Efficient data management is crucial for maximizing HTS's potential in CHD research. Computational tools like CustOmics, which integrate multi-omics data through a two-phase deep learning process, exemplify progress in managing large datasets and extracting meaningful insights [22]. These tools help identify key genetic and molecular pathways involved in CHD, offering potential therapeutic targets.

Research methods, categorized into stages like feature selection, clinical outcome prediction, and clustering for subtype discovery, provide a structured approach to integrating multi-omics data [19]. This framework enhances our understanding of CHD by facilitating the identification of new biomarkers and therapeutic targets.

Recent findings underscore the significance of lipid-related pathways, such as lipophagy, in atherosclerosis and CHD. Identifying lipophagy receptors and developing lipophagy-inducing compounds represent substantial progress in therapeutic strategies for atherosclerosis, a major CHD contributor [36]. Additionally, the role of oxysterols in atherosclerosis pathophysiology highlights the importance of lipid metabolism in CHD development [37].

Methodological advancements like ComHapDet, which utilizes spatial locality for accurate haplotype recovery, mitigate the impact of sequencing errors [38]. MIXALIME provides a robust statistical framework for estimating allelic imbalance by modeling allelic read counts while accounting for biases and noise characteristics [39]. These advancements enhance the accuracy of genetic analyses in CHD research.

The 'seqphase' method utilizes local phasing information from sequencing reads to guide haplotype inference, showcasing technological advancements pertinent to CHD research [40]. Sparse statistical modeling has improved the analysis of gene expression data, enhancing the identification of significant gene-environment interactions related to disease risk [29]. The Predictive Risk Assessment methodology (PRAA) employs advanced imputation strategies and intelligent feature selection to enhance prediction accuracy for atherosclerosis, a critical aspect of CHD [7].

3.2 Applications in Cardiovascular Genomics

High-throughput sequencing (HTS) technologies have transformed cardiovascular genomics, enabling detailed exploration of genetic variations associated with coronary heart disease (CHD). Innovations in sequencing technologies, including next-generation sequencing (NGS) and single-cell RNA sequencing (scRNA-seq), have reduced costs and time while enhancing throughput and accuracy, broadening their applications in genomics and personalized medicine [21]. These technologies

AI-generated, for reference only.



Figure 3: This figure illustrates the key advancements in high-throughput sequencing technologies for cardiovascular research, focusing on sequencing innovations, data integration methodologies, and lipid metabolism pathways in coronary heart disease.

facilitate the identification of genetic variants contributing to CHD risk, deepening our understanding of the disease's genetic architecture.

A primary application of HTS in cardiovascular genomics is identifying single nucleotide polymorphisms (SNPs) and other genetic variants influencing CHD susceptibility. Wavelet-based genetic association analysis enhances the detection of genetic variants linked to disease phenotypes by transforming sequencing data into wavelet coefficients [34]. This method exemplifies how integrating advanced computational techniques with HTS can uncover genetic variations contributing to cardiovascular risk.

The application of scRNA-seq has yielded novel insights into cellular heterogeneity and disease mechanisms. By identifying cell types and analyzing cellular differentiation, scRNA-seq elucidates molecular pathways involved in CHD pathogenesis, offering potential therapeutic targets [32]. This technology enables researchers to investigate complex cellular interactions within cardiovascular tissues, advancing our understanding of disease processes at a single-cell level.

HTS also integrates with pharmacogenomics, exemplified by frameworks that elucidate CYP2C19 genetic polymorphisms. This integration facilitates the application of pharmacogenetic insights in cardiovascular genomics, enabling personalized medicine strategies that optimize therapeutic outcomes based on individual genetic profiles [1]. By tailoring treatments to genetic predispositions, HTS contributes to developing personalized interventions that enhance patient care in cardiovascular diseases.

Furthermore, HTS supports modeling complex biological systems through frameworks like the deep belief network model (DBNM), which utilizes HTS data to analyze and predict outcomes in biological systems by learning intricate nonlinear relationships directly from the data [41]. Such models enhance the predictive power of genomic analyses, providing valuable insights into disease progression and treatment responses.

The use of volunteer computing resources, as demonstrated by Coinami, addresses computational challenges associated with HTS read mapping. By effectively utilizing distributed computing power, Coinami provides a viable solution for managing the vast amounts of data generated by HTS, facilitating genomic data analysis in cardiovascular research [42].

The applications of high-throughput sequencing in cardiovascular genomics are extensive, significantly impacting healthcare by facilitating the identification of genetic variations contributing to coronary heart disease. This genomic insight is crucial for advancing personalized medicine and developing targeted therapeutic strategies. Recent advancements in multidimensional integrative genomics, combining various omics data types—including genomics, epigenomics, transcriptomics, and proteomics—enhance our understanding of the complex molecular mechanisms underlying cardiovascular diseases. As large-scale genome sequencing initiatives expand, they promise to yield valuable data for identifying at-risk populations and informing the development of precision medicine approaches tailored to individual genetic profiles [10, 43, 2, 3, 9]. The integration of advanced computational methods and innovative technologies continues to enhance the field, offering new opportunities for understanding and managing cardiovascular diseases.

3.3 Computational Challenges and Solutions

The analysis of high-throughput sequencing (HTS) data in cardiovascular genomics presents significant computational challenges, primarily due to the vast data volume generated and the complexity of its analysis. A major issue is the 'curse of dimensionality,' which complicates the integration and interpretation of diverse omics data, reducing the prediction performance of existing methods [22]. This challenge is further exacerbated by data heterogeneity, creating additional hurdles in achieving accurate results.

A critical bottleneck in HTS is the substantial computational resources required for read mapping, often demanding approximately 30 CPU days per human genome [42]. This intensive requirement underscores the necessity for more efficient computational frameworks to manage the increasing volume of sequencing data. Current methods frequently sacrifice sensitivity for speed, inadequately accounting for the statistical properties of reads, which leads to inefficiencies in read mapping [44]. Moreover, the dynamic nature of read mapping often results in erroneous placements and biases toward alleles present in the reference genome [45].

The rapid data generation rate of HTS technologies compounds these challenges, as significant data movement between computation and memory units results in the generation of extraneous data during analysis [46]. This inefficiency necessitates innovative solutions to streamline data processing and enhance computational efficiency.

Several methodological advancements have been proposed to address these challenges. MIXALIME, for instance, integrates multiple statistical approaches to improve the detection of allelic imbalance, particularly in the presence of noise and bias [39]. This integration is essential for enhancing the accuracy of genomic analyses. Additionally, DeepCoDA maintains interpretability while effectively modeling interactions between features in a compositional context, providing a robust framework for genomic data analysis [47].

The Generalized Estimating Equations (GEE) approach allows for robust estimation of population pharmacokinetic parameters without requiring random effects, making it suitable for large-scale pharmacogenomic studies [31]. This approach is particularly advantageous in handling the large datasets typical of cardiovascular genomics research.

4 Genetic Polymorphisms and Predispositions

Category	Feature	Method
Identification and Analysis of Genetic Variants	Statistical and Predictive Modeling Real-Time Data Adjustment	kruX[18], SSM[29], PRAA[7] DRM[45]
Specific Genetic Variants Linked to CHD	Expression and Mapping Techniques Error Minimization Strategies	PRSD[44], MIX[39] SP[40]
Multi-Omics Approaches in Understanding Genetic Predispositions	Hybrid Integration Strategies	CustOmics[22]

Table 1: This table provides a comprehensive summary of methodologies utilized in the identification and analysis of genetic variants, specifically those linked to coronary heart disease (CHD). It categorizes the methods based on their features and the specific approaches they employ, highlighting advancements in statistical modeling, real-time data adjustment, expression and mapping techniques, error minimization strategies, and multi-omics integration.

Understanding the methodologies for identifying and analyzing genetic variants is crucial for elucidating the genetic underpinnings of diseases like coronary heart disease (CHD). Table 1 presents a detailed overview of the methodologies employed in the identification and analysis of genetic variants associated with CHD, emphasizing their categorization and specific features. These methodologies highlight advancements in genomic technologies that enable deeper exploration of genetic predispositions to CHD, setting the stage for further research and clinical applications.

4.1 Identification and Analysis of Genetic Variants

The detection and analysis of genetic variants associated with CHD are pivotal for understanding its genetic basis and developing targeted interventions. Genome-wide association studies (GWAS) have identified numerous single-nucleotide polymorphisms (SNPs) linked to CHD, though they often explain only a fraction of phenotypic variance [18]. Advanced methodologies such as MIXALIME and the Position-Restricted Seed Design (PRSD) framework enhance variant detection by improving allelic imbalance assessment and optimizing read mapping sensitivity, respectively [39, 44].

Dynamic read mapping refines variant analysis accuracy by adjusting reference sequences based on incoming data [45]. The 'seqphase' method leverages local phasing information to improve haplotype inference, crucial for identifying rare variants contributing to CHD risk [40]. Sparse Statistical Modeling (SSM) identifies significant gene interactions in high-dimensional data, enhancing our understanding of CHD's genetic architecture [29]. The PRAA methodology further improves CHD risk prediction by imputing missing values and extracting influential features [7].

These sophisticated computational tools and experimental models collectively advance the identification and analysis of genetic variants, facilitating targeted therapeutic interventions [43, 3, 10]. As depicted in Figure 4, the hierarchical structure of genetic variant analysis categorizes key detection methods, analysis techniques, and their applications in understanding and managing coronary heart disease. This visual representation underscores the interconnectedness of these methodologies and their collective impact on advancing our knowledge of CHD.



Figure 4: This figure illustrates the hierarchical structure of genetic variant analysis, categorizing key detection methods, analysis techniques, and their applications in understanding and managing coronary heart disease.

4.2 Specific Genetic Variants Linked to CHD

Advancements in identifying specific genetic variants linked to CHD have significantly enhanced our understanding of its genetic foundations. Approximately 60 genetic loci associated with CHD have been identified, emphasizing their integration into clinical practice for improved risk prediction [3]. MicroRNA polymorphisms are notable biomarkers for assessing CHD risk [14]. KIV-2 copy number variation correlates with lipoprotein(a) levels, a key risk factor for atherosclerosis and CHD [15].

MIXALIME excels in estimating allelic imbalance in complex datasets, improving the precision of variant identification [39]. The PRSD framework enhances read mapping accuracy by employing strategic seed placement [44]. The 'seqphase' method reduces switch error rates in haplotype inference, particularly for rare variants linked to early-onset CHD [40]. Apolipoprotein B's strong association with CHD underscores its role as a genetic variant linked to increased risk [5].

Mouse models, including Ldlr and Apoe knockout mice, are instrumental in elucidating the genetic and pathophysiological mechanisms underlying atherosclerosis, offering insights into lipid metabolism and inflammatory processes [10, 18, 48, 49, 3].

4.3 Multi-Omics Approaches in Understanding Genetic Predispositions

Multi-omics approaches have transformed our understanding of genetic predispositions to CHD by integrating genomics, epigenomics, transcriptomics, metabolomics, and proteomics. This comprehensive methodology surpasses the limitations of single-omics analyses, providing a holistic view of the molecular interactions underlying CHD [50].

Advancements in single-cell RNA sequencing (scRNA-seq) have enhanced omics data resolution, facilitating exploration of cellular heterogeneity in cardiovascular tissues. The integration of scRNA-seq with multi-omics data promises personalized medicine strategies tailored to individual genetic profiles, improving therapeutic outcomes [32].

CustOmics exemplifies novel computational frameworks that integrate multi-omics data using a hybrid mixed-integration strategy, enhancing predictive accuracy and managing high-dimensional data effectively [22]. Future research should focus on universal integration pipelines leveraging deep learning for comprehensive data source integration [50].

In atherosclerosis, multi-omics approaches have identified critical roles for T cells and specific cytokines in disease progression, offering potential therapeutic targets. This integration enables a comprehensive analysis of immune pathways, elucidating interactions between genetic predispositions and immune responses [51]. Categorizing imputation methods into single-omics and integrative multi-omics approaches highlights the benefits of leveraging inter-omics correlations for improved accuracy [52]. Additionally, exploring different wavelet bases in genetic association analyses may enhance the detection of disease-linked genetic variants [34, 44].

5 Familial Hypercholesterolemia and Its Genetic Basis

5.1 Familial Hypercholesterolemia: Genetic Basis and CHD Risk

Familial hypercholesterolemia (FH) is an autosomal-dominant disorder characterized by elevated low-density lipoprotein (LDL) cholesterol, significantly increasing premature coronary heart disease (CHD) risk. Mutations primarily occur in the LDL receptor (LDLR) pathway, disrupting cholesterol metabolism and causing severe hypercholesterolemia [53]. FH manifests as heterozygous (HeFH) or homozygous (HoFH), with HoFH leading to more severe clinical outcomes due to two defective alleles.

The impact of FH on CHD risk is profound, with affected individuals experiencing accelerated atherosclerosis and early cardiovascular events [54]. Elevated LDL cholesterol from a young age contributes to premature atherosclerotic plaque formation, a hallmark of CHD. The underdiagnosis and undertreatment of FH exacerbate cardiovascular complications, highlighting the need for improved detection and management strategies [55].

Genetic research emphasizes the importance of early detection and family-based screening in managing FH. Frameworks for diagnosis and management advocate genetic testing and family involvement to identify affected individuals and initiate timely interventions [56]. Innovative diagnostic methods, such as the FHTabNet multiclass model, enhance FH diagnosis accuracy and support personalized treatment plans [57].

5.2 Diagnostic Challenges and Advances

Diagnosing familial hypercholesterolemia (FH) is challenging due to variability in diagnostic criteria and screening strategies across populations, complicating prevalence assessments in diverse ethnic groups [58]. This variability often results in underestimating FH prevalence, particularly in underrepresented populations, due to heterogeneous diagnostic criteria and insufficient data [58]. Additionally, the complexity and cost of conventional diagnostic methods contribute to high underdiagnosis rates [57].

Underdiagnosis is critical, with current tools failing to identify affected individuals effectively; fewer than 1

Recent advancements highlight the importance of family screening and genetic testing, essential for early FH detection and management despite being underutilized [56]. Innovative diagnostic models, like the FHTabNet multiclass model, aim to improve FH diagnosis accuracy and efficiency, potentially reducing underdiagnosis rates and facilitating tailored treatment approaches [57].

6 Implications for Interventions and Treatments

A comprehensive management strategy for early onset coronary heart disease (CHD) integrates genetic insights and innovative treatments, focusing on personalized care to improve patient outcomes. This section examines various management and treatment strategies, highlighting their role in customizing interventions for individuals at risk of CHD.

6.1 Management and Treatment Strategies

Effective management of early onset CHD requires integrating genetic insights, pharmacogenomics, and innovative interventions. Genetic testing and family studies are crucial, particularly for familial hypercholesterolemia (FH), in identifying high-risk individuals and tailoring interventions [53]. Advanced diagnostic tools like FH-TabNet classify patients into risk categories, facilitating personalized treatment plans [57].

Pharmacogenomic insights enhance treatment personalization by emphasizing drug-gene interactions affecting drug metabolism and efficacy [59]. Implementing genetic-based medication adjustments and considering gene-diet interactions in cardiovascular disease (CVD) risk management underscores the potential of precision nutrition in managing CHD [9].

The survey emphasizes early detection and intervention for dyslipidemia in children to promote cardiovascular health [6]. Richardson et al. advocate targeting apolipoprotein B in lipid-modifying therapies, highlighting its importance in early onset CHD interventions [5].

Emerging research underscores the significance of epicardial adipose tissue (EAT) assessments through fat-omics for cardiovascular risk prediction, suggesting new pathways for refining risk assessments [60]. Future studies should explore ApoB100-targeted interventions and genetic factors influencing lipid metabolism and CVD [61].

Platforms like GobyWeb enhance genomic data management and analysis, integrating advanced analytics and cloud compatibility to bolster cardiovascular genomics research [62]. Leveraging these technologies can improve early onset CHD management and treatment, reducing disease burden and enhancing patient outcomes.

6.2 Pharmacogenomics and Personalized Medicine

Pharmacogenomics is foundational to precision medicine in CVD, allowing for personalized treatment plans based on genetic information [59]. This approach optimizes medication efficacy and safety, accommodating genetic variability. Implementing pharmacogenomic testing for CVD medications tailors treatments to genetic profiles, underscoring pharmacogenomics' clinical potential [59].

Advancements in CAD genetics have identified novel therapeutic targets and personalized strategies [3]. Pharmacogenomics applies genomic and epigenetic biomarkers to guide therapeutic decisions, as seen in APS management [16]. These biomarkers provide insights into patient-specific disease mechanisms, enabling customized treatment plans.

The DeepCoDA framework integrates pharmacogenomics with computational models, extending precision health modeling to complex data with personalized interpretability [47]. The Generalized Estimating Equations (GEE) method offers computational advantages, enhancing pharmacogenomic analysis precision and supporting tailored interventions [31].

6.3 Innovative Therapeutic Strategies

Innovative therapeutic strategies targeting genetic and molecular pathways in atherosclerosis and CHD are informed by genomic advances. Identifying genetic factors like BRCA2 as therapeutic targets highlights the importance of understanding genetic interactions for novel interventions [54]. These strategies leverage genetic insights to design targeted therapies addressing cardiovascular disease root causes.

MicroRNA pathways in diabetes and CVD represent promising therapeutic avenues. Targeting these pathways may lead to treatments that modulate gene expression and slow disease progression [14]. Future research should validate these findings across diverse populations to ensure broad applicability.

Targeting inflammatory pathways, particularly NLRP3 and TLRs, offers a promising strategy for atherosclerosis treatment [30]. Modulating immune responses can improve outcomes by reducing inflammation and stabilizing plaques [26].

Oxysterols, significant in atherosclerosis, have emerged as potential therapeutic targets. Understanding their impact on vascular cells may lead to interventions that specifically target these molecules, potentially reducing plaque formation [37]. Exploring lipophagy as a treatment approach may promote cholesterol efflux and reduce plaque formation [36].

The antigen specificity of T cells in atherosclerosis is a critical area for exploration. Elucidating these specificities could lead to strategies like tolerogenic vaccines and targeted immunotherapies to modulate immune responses and prevent progression [51]. Understanding molecular mechanisms in atherosclerosis, as demonstrated in mouse models, is essential for identifying new therapeutic targets [48].

Pharmacogenomics plays an increasing role in cardiovascular medicine, enabling personalized treatments such as warfarin dosing and antiplatelet selection based on genetic profiles. Advancements in sequencing technologies enhance personalized medicine potential, allowing clinicians to stratify patients using genetic information. However, further research, clinical trials, and tools like polygenic risk scores are necessary to integrate these approaches into standard care. As pharmacogenomics evolves, healthcare providers must navigate genetic data complexities to improve outcomes [63, 43, 10]. This approach enhances treatment efficacy by tailoring interventions to genetic makeup, optimizing therapeutic outcomes.

6.4 Multi-Omics and Precision Health

Multi-omics approaches advance precision health by providing a comprehensive understanding of the complex biological interactions underlying CHD. Integrating genomics, transcriptomics, proteomics, and metabolomics offers a holistic perspective on disease mechanisms, facilitating the identification of novel biomarkers and therapeutic targets. Computational frameworks like CustOmics enhance multi-omics data integration, demonstrating superior performance in classifying and analyzing survival data, highlighting its effectiveness in precision medicine [22].

Multi-omics studies uncover intricate interactions between genetic factors and CVD, essential for developing targeted therapies and advancing precision health. Analyzing gene expression patterns influenced by environmental and genetic interactions provides insights into atherosclerosis mechanisms [29]. This underscores the importance of multi-omics in understanding CHD's multifactorial nature and identifying therapeutic intervention pathways.

Future research should refine anti-inflammatory therapies, understand mechanisms, and explore personalized approaches based on genetic and inflammatory profiles [28]. Investigating pathways involving oxysterols is critical for understanding their atherosclerosis role and developing targeted therapies. Furthermore, exploring genetic factors in resolution failure and resolution therapies' clinical applications are promising areas for mechanistic studies.

Developing interpretable deep learning models like DeepCoDA, achieving personalized interpretability in compositional health data while maintaining performance, is vital for advancing multi-omics research [47]. Additionally, dynamic mapping approaches enhance read alignment and variant calling accuracy, contributing to precision health in CHD treatment [45].

7 Conclusion

7.1 Future Research Directions

Advancing research in coronary heart disease (CHD) necessitates the development of robust models that accurately mirror human atherosclerosis, with a particular emphasis on the roles of microRNAs and innovative therapeutic strategies like nanomedicine. Understanding the biological mechanisms underlying genetic risk factors for coronary artery disease (CAD) is crucial, as is the integration of genetic data into clinical settings to enhance risk stratification and treatment. Longitudinal studies play a vital role in exploring the long-term effects of early diagnosis and the efficacy of interventions, especially concerning age-related risk mechanisms.

The adoption of multi-omics approaches and the development of flexible trans-omic methodologies are essential to deepen our understanding of CHD pathogenesis. These approaches should be inclusive of diverse populations to uncover sex-specific mechanisms and apply novel statistical methods for comprehensive data analysis. Enhancements in single-cell analysis, integration with spatial techniques, and the establishment of standardized protocols will be pivotal in improving reproducibility and data sharing. Furthermore, refining genetic instruments and examining additional lipid traits will propel genetic research forward.

Exploring gene-environment interactions and validating results across varied populations are imperative for comprehending CHD's multifactorial nature. Establishing pharmacogenomic testing guidelines and leveraging big data for clinical translation of genetic insights will be key. Enhancements in the Generalized Estimating Equation (GEE) method, or alternative modeling approaches that integrate GEE with nonlinear mixed-effect models (NLMM), could significantly improve the precision of pharmacogenomic analyses.

Efforts should also focus on refining multi-omics techniques and exploring emerging trends in personalized medicine to enhance cardiovascular disease management. The development of deep learning methods capable of integrating diverse data types, improving interpretability, and utilizing larger datasets is critical. Validation of findings with larger, more diverse populations and the integration of fat-omics with cardiovascular risk assessment tools are essential. Additionally, improving the scalability of predictive risk assessment methodologies for broader cardiovascular health applications remains a priority.

Finally, addressing challenges related to data movement and storage, integrating multiple analysis steps, and developing efficient algorithms alongside specialized hardware for genome analysis are crucial for future progress. Optimizing methods for larger datasets and enhancing error detection in sequencing reads will further illuminate genetic predispositions in CHD.

References

[1] Zhixiong Zhong, Jingyuan Hou, Bing Li, Qifeng Zhang, Sudong Liu, Cunren Li, Zhidong Liu, Min Yang, Wei Zhong, and Pingsen Zhao. Analysis of cyp2c19 genetic polymorphism in a large ethnic hakka population in southern china. *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*, 23:6186, 2017.

[2] Stella Aslibekyan and Edward A Ruiz-Narváez. The state of cardiovascular genomics: Abundant data, limited information. *Revista espanola de cardiologia (English ed.)*, 70(9):696, 2017.

[3] Amit V Khera and Sekar Kathiresan. Genetics of coronary artery disease: discovery, biology and clinical translation. *Nature Reviews Genetics*, 18(6):331–344, 2017.

[4] Araz Rawshani, Naveed Sattar, Stefan Franzén, Aidin Rawshani, Andrew T Hattersley, Ann-Marie Svensson, Björn Eliasson, and Soffia Gudbjörnsdottir. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. *The Lancet*, 392(10146):477–486, 2018.

[5] Tom G Richardson, Eleanor Sanderson, Tom M Palmer, Mika Ala-Korpela, Brian A Ference, George Davey Smith, and Michael V Holmes. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable mendelian randomisation analysis. *PLoS medicine*, 17(3):e1003062, 2020.

[6] Comment.

[7] V. Sree Hari Rao and M. Naresh Kumar. Novel approaches for predicting risk factors of atherosclerosis, 2015.

[8] Mathilde Sautreuil, Sarah Lemler, and Paul-Henry Cournède. Neural networks to predict survival from rna-seq data in oncology, 2021.

[9] V Saroja Voruganti. Nutritional genomics of cardiovascular disease. *Current genetic medicine reports*, 6:98–106, 2018.

[10] Paola Leon-Mimila, Jessica Wang, and Adriana Huertas-Vazquez. Relevance of multi-omics studies in cardiovascular diseases. *Frontiers in cardiovascular medicine*, 6:91, 2019.

[11] Xuejing Yu, Xianggui Yang, and Jinjin Cao. Application of single-cell genomics in cardiovascular research. *Cardiology and Therapy*, 12(1):101–125, 2023.

[12] Kamel Mohammedi, Michel Marre, and François Alhenc-Gelas. Genetic predisposition to nephropathy and associated cardiovascular disease in people with type 1 diabetes: role of the angiotensini-converting enzyme (ace), and beyond; a narrative review. *Cardiovascular Diabetology*, 23(1):453, 2024.

[13] Md Mehadi Hasan Sohag, Saleh Muhammed Raqib, and Syaefudin Ali Akhmad. Omics approaches in cardiovascular diseases: a mini review. *Genomics & Informatics*, 19(2):e13, 2021.

[14] Imadeldin Elfaki, Rashid Mir, Mohammad Muzaffar Mir, Faisel M AbuDuhier, Abdullatif Taha Babakr, and Jameel Barnawi. Potential impact of microrna gene polymorphisms in the pathogenesis of diabetes and atherosclerotic cardiovascular disease. *Journal of personalized medicine*, 9(4):51, 2019.

[15] Sairam Behera, Jonathan R Belyeu, Xiao Chen, Luis F Paulin, Ngoc Quynh H Nguyen, Emma Newman, Medhat Mahmoud, Vipin K Menon, Qibin Qi, Parag Joshi, et al. Identification of allele-specific kiv-2 repeats and impact on lp (a) measurements for cardiovascular disease risk. *BMC medical genomics*, 17(1):255, 2024.

[16] Chary Lopez-Pedrera, Nuria Barbarroja, Alejandra Mª Patiño-Trives, Eduardo Collantes, Mª Angeles Aguirre, and Carlos Perez-Sanchez. New biomarkers for atherothrombosis in antiphospholipid syndrome: genomics and epigenetics approaches. *Frontiers in immunology*, 10:764, 2019.

[17] Graham Coop. Reading tea leaves? polygenic scores and differences in traits among groups, 2019.

[18] Hassan Foroughi Asl. eqtl mapping and inherited risk enrichment analysis : a systems biology approach for coronary artery disease, 2016.

[19] Mingon Kang, Euiseong Ko, and Tesfaye B Mersha. A roadmap for multi-omics data integration using deep learning. *Briefings in Bioinformatics*, 23(1):bbab454, 2022.

[20] Tianwei Yue, Yuanxin Wang, Longxiang Zhang, Chunming Gu, Haoru Xue, Wenping Wang, Qi Lyu, and Yujie Dun. Deep learning for genomics: A concise overview, 2023.

[21] Olaitan Akintunde, Trichina Tucker, and Valerie J. Carabetta. The evolution of next-generation sequencing technologies, 2023.

[22] Hakim Benkirane, Yoann Pradat, Stefan Michiels, and Paul-Henry Cournède. Customics: A versatile deep-learning based strategy for multi-omics integration, 2022.

[23] Xinggang Wang, Aijun Sun, and Junbo Ge. Medial injury/dysfunction induced granulation tissue repair is the pathogenesis of atherosclerosis, 2020.

[24] Ishraq U. Ahmed, Helen M. Byrne, and Mary R. Myerscough. Macrophage anti-inflammatory behaviour in a multiphase model of atherosclerotic plaque development, 2022.

[25] L Maximilian Buja. Pathogenesis of atherosclerosis: A multifactorial process. *Ischemic Heart Disease: From Diagnosis to Treatment*, pages 15–37, 2023.

[26] Beatriz Herrero-Fernandez, Raquel Gomez-Bris, Beatriz Somovilla-Crespo, and Jose Maria Gonzalez-Granado. Immunobiology of atherosclerosis: a complex net of interactions. *International Journal of Molecular Sciences*, 20(21):5293, 2019.

[27] Canan Kasikara, Amanda C Doran, Bishuang Cai, Ira Tabas, et al. The role of non-resolving inflammation in atherosclerosis. *The Journal of clinical investigation*, 128(7):2713–2723, 2018.

[28] Oliver Soehnlein and Peter Libby. Targeting inflammation in atherosclerosis—from experimental insights to the clinic. *Nature reviews Drug discovery*, 20(8):589–610, 2021.

[29] David M. Seo, Pascal J. Goldschmidt-Clermont, and Mike West. Of mice and men: Sparse statistical modeling in cardiovascular genomics, 2007.

[30] Peng Kong, Zi-Yang Cui, Xiao-Fu Huang, Dan-Dan Zhang, Rui-Juan Guo, and Mei Han. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. *Signal transduction and targeted therapy*, 7(1):131, 2022.

[31] Kengo Nagashima, Yasunori Sato, Hisashi Noma, and Chikuma Hamada. An efficient and robust method for analyzing population pharmacokinetic data in genome-wide pharmacogenomic studies: a generalized estimating equation approach, 2018.

[32] David T Paik, Sangkyun Cho, Lei Tian, Howard Y Chang, and Joseph C Wu. Single-cell rna sequencing in cardiovascular development, disease and medicine. *Nature Reviews Cardiology*, 17(8):457–473, 2020.

[33] Hyun Min Kang, Meena Subramaniam, Sasha Targ, Michelle Nguyen, Lenka Maliskova, Elizabeth McCarthy, Eunice Wan, Simon Wong, Lauren Byrnes, Cristina M Lanata, et al. Multiplexed droplet single-cell rna-sequencing using natural genetic variation. *Nature biotechnology*, 36(1):89–94, 2018.

[34] Heejung Shim and Matthew Stephens. Wavelet-based genetic association analysis of functional phenotypes arising from high-throughput sequencing assays, 2013.

[35] Piotr Nyczka, Johannes Falk, and Marc-Thorsten Hütt. Network location and clustering of genetic mutations determine chronicity in a stylized model of genetic diseases, 2022.

[36] Thomas Laval and Mireille Ouimet. A role for lipophagy in atherosclerosis. *Nature Reviews Cardiology*, 20(7):431–432, 2023.

[37] Celine Luquain-Costaz and Isabelle Delton. Oxysterols in vascular cells and role in atherosclerosis, 2024.

[38] Abishek Sankararaman, Haris Vikalo, and François Baccelli. Comhapdet: A spatial community detection algorithm for haplotype assembly, 2019.

[39] Georgy Meshcheryakov, Sergey Abramov, Aleksandr Boytsov, Andrey I. Buyan, Vsevolod J. Makeev, and Ivan V. Kulakovskiy. Mixalime: Mixture models for allelic imbalance estimation in high-throughput sequencing data, 2024.

[40] Fouad Zakharia and Carlos Bustamante. Improved haplotyping of rare variants using next-generation sequence data, 2012.

[41] Michael G. Watson, Helen M. Byrne, Charlie Macaskill, and Mary R. Myerscough. A two-phase model of early fibrous cap formation in atherosclerosis, 2018.

[42] Atalay M. Ileri, Halil I. Ozercan, Alper Gundogdu, Ahmet K. Senol, M. Yusuf Ozkaya, and Can Alkan. Coinami: A cryptocurrency with dna sequence alignment as proof-of-work, 2016.

[43] Douglas Arneson, Le Shu, Brandon Tsai, Rio Barrere-Cain, Christine Sun, and Xia Yang. Multidimensional integrative genomics approaches to dissecting cardiovascular disease. *Frontiers in cardiovascular medicine*, 4:8, 2017.

[44] Laurent Noé, Marta L. Gîrdea, and Gregory Kucherov. Seed design framework for mapping solid reads, 2010.

[45] Karel Břinda, Valentina Boeva, and Gregory Kucherov. Dynamic read mapping and online consensus calling for better variant detection, 2016.

[46] Onur Mutlu and Can Firtina. Accelerating genome analysis via algorithm-architecture co-design, 2023.

[47] Thomas P. Quinn, Dang Nguyen, Santu Rana, Sunil Gupta, and Svetha Venkatesh. Deepcoda: personalized interpretability for compositional health data, 2020.

[48] Yee Ting Lee, Hiu Yu Lin, Yin Wah Fiona Chan, Ka Hou Christien Li, Olivia Tsz Ling To, Bryan P Yan, Tong Liu, Guangping Li, Wing Tak Wong, Wendy Keung, et al. Mouse models of atherosclerosis: a historical perspective and recent advances. *Lipids in health and disease*, 16:1–11, 2017.

[49] Sara Oppi, Thomas F Lüscher, and Sokrates Stein. Mouse models for atherosclerosis research—which is my line? *Frontiers in cardiovascular medicine*, 6:46, 2019.

[50] Nasim Vahabi and George Michailidis. Unsupervised multi-omics data integration methods: a comprehensive review. *Frontiers in genetics*, 13:854752, 2022.

[51] Ryosuke Saigusa, Holger Winkels, and Klaus Ley. T cell subsets and functions in atherosclerosis. *Nature Reviews Cardiology*, 17(7):387–401, 2020.

[52] Meng Song, Jonathan Greenbaum, Joseph Luttrell IV, Weihua Zhou, Chong Wu, Hui Shen, Ping Gong, Chaoyang Zhang, and Hong-Wen Deng. A review of integrative imputation for multi-omics datasets. *Frontiers in genetics*, 11:570255, 2020.

[53] Atsushi Nohara, Hayato Tada, Masatsune Ogura, Sachiko Okazaki, Koh Ono, Hitoshi Shimano, Hiroyuki Daida, Kazushige Dobashi, Toshio Hayashi, Mika Hori, et al. Homozygous familial hypercholesterolemia. *Journal of atherosclerosis and thrombosis*, 28(7):665–678, 2021.

[54] David C. R. Michels, Sepideh Nikfarjam, Berk Rasheed, Margi Patel, Shuhan Bu, Mehroz Ehsan, Hien C. Nguyen, Aman Singh, Biao Feng, John McGuire, Robert Gros, Jefferson C. Frisbee, and Krishna K. Singh. Endothelial cell-specific loss of breast cancer susceptibility gene 2 exacerbates atherosclerosis, 2023.

[55] Maria Mytilinaiou, Ioannis Kyrou, Mike Khan, Dimitris K Grammatopoulos, and Harpal S Randeva. Familial hypercholesterolemia: New horizons for diagnosis and effective management. *Frontiers in pharmacology*, 9:707, 2018.

[56] Mariko Harada-Shiba, Hidenori Arai, Yasushi Ishigaki, Shun Ishibashi, Tomonori Okamura, Masatsune Ogura, Kazushige Dobashi, Atsushi Nohara, Hideaki Bujo, Katsumi Miyauchi, et al. Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. *Journal of Atherosclerosis and Thrombosis*, 25(8):751–770, 2018.

[57] Sadaf Khademi, Zohreh Hajiakhondi, Golnaz Vaseghi, Nizal Sarrafzadegan, and Arash Mohammadi. Fh-tabnet: Multi-class familial hypercholesterolemia detection via a multi-stage tabular deep learning, 2024.

[58] Frida Toft-Nielsen, Frida Emanuelsson, and Marianne Benn. Familial hypercholesterolemia prevalence among ethnicities—systematic review and meta-analysis. *Frontiers in Genetics*, 13:840797, 2022.

[59] Zeina N Al-Mahayri, Lubna Q Khasawneh, Mais N Alqasrawi, Sahar M Altoum, Gohar Jamil, Sally Badawi, Dana Hamza, Lizy George, Anwar AlZaabi, Husam Ouda, et al. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in united arab emirates. *Human Genomics*, 16(1):42, 2022.

[60] Tao Hu, Joshua Freeze, Prerna Singh, Justin Kim, Yingnan Song, Hao Wu, Juhwan Lee, Sadeer Al-Kindi, Sanjay Rajagopalan, David L. Wilson, and Ammar Hoori. Ai prediction of cardiovascular events using opportunistic epicardial adipose tissue assessments from ct calcium score, 2024.

[61] Dimitris Kounatidis, Natalia G Vallianou, Aikaterini Poulaki, Angelos Evangelopoulos, Fotis Panagopoulos, Theodora Stratigou, Eleni Geladari, Irene Karampela, and Maria Dalamaga. Apob100 and atherosclerosis: What's new in the 21st century? *Metabolites*, 14(2):123, 2024.

[62] Kevin C. Dorff, Nyasha Chambwe, Zachary Zeno, Rita Shaknovich, and Fabien Campagne. Gobyweb: simplified management and analysis of gene expression and dna methylation sequencing data, 2012.

[63] Invited review article.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.

AI-generated, for reference only.